Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report)’s stock price traded down 7.8% during trading on Friday . The company traded as low as $12.65 and last traded at $12.76. 26,772 shares were traded during mid-day trading, a decline of 61% from the average session volume of 68,420 shares. The stock had previously closed at $13.84.
Gyre Therapeutics Price Performance
The stock’s fifty day moving average is $13.83 and its 200 day moving average is $12.98.
Institutional Trading of Gyre Therapeutics
Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after acquiring an additional 90,557 shares in the last quarter. State Street Corp increased its position in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after acquiring an additional 8,412 shares during the period. Advantage Alpha Capital Partners LP bought a new stake in shares of Gyre Therapeutics during the third quarter valued at approximately $334,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $220,000. Institutional investors own 23.99% of the company’s stock.
About Gyre Therapeutics
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- What is a Death Cross in Stocks?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- 3 Warren Buffett Stocks to Buy Now
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Health Care Stocks Explained: Why You Might Want to Invest
- Time to Load Up on Home Builders?
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
